Outcomes after Bone Marrow Versus Peripheral Blood Mismatched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis

Key Points

• Bone marrow and peripheral blood transplantation show comparable outcomes when using posttransplant cyclophosphamide for GVHD prevention.
• The key metric indicates overall survival rates are similar between the two donor types after transplantation.
• Analysis of transplant results in a cohort reveals critical insights into mismatched donor procedures and their effectiveness.
• Findings support the use of either bone marrow or peripheral blood while highlighting the importance of GVHD management.